Wave reports Phase 1 durability for WVE-006; advances RestorAATion-2 registrational trial

Wave Life Sciences/WVE-006

Wave presented Phase 1 data showing WVE-006 was well tolerated and edits persisted through follow-up. An independent monitoring committee cleared advancement to RestorAATion-2, a 24-month registrational trial with interim analysis for potential accelerated FDA approval.

• Phase 1 edits persisted over follow-up, supporting potential durable single-dose therapy.
• RestorAATion-2 interim analysis designed to support accelerated approval pathway.
• WVE-006 remains first and only clinical ADAR-mediated RNA editing therapy for genetic disease.